Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Day One Biopharma to acquire Mersana Therapeutics for up to $285M to boost its cancer drug pipeline.

flag Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics in a deal worth up to $285 million, including an upfront $25 per share cash payment and potential milestone-based payments of up to $30.25 per share. flag The acquisition, pending regulatory and shareholder approval, aims to expand Day One’s oncology pipeline, particularly in pediatric cancers, and integrate Mersana’s antibody-drug conjugate platform and clinical-stage candidates. flag Mersana’s lead drug, Emi-Le, is a key focus. flag Day One reported strong third-quarter sales of its lead drug, tovorafenib, with revenue rising to $38.5 million and prescriptions increasing 18% quarter-over-quarter. flag The company raised its 2025 revenue forecast for tovorafenib to $145–$150 million and ended the quarter with $451.6 million in cash. flag The tender offer is expected to begin within 10 business days of November 12, 2025.

5 Articles

Further Reading